Day One Biopharmaceuticals (NASDAQ:DAWN) Announces Quarterly Earnings Results

Day One Biopharmaceuticals (NASDAQ:DAWN) announced its earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.70, Yahoo Finance reports. The business had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $0.90 million.

Day One Biopharmaceuticals Trading Down 1.0 %

DAWN traded down $0.14 on Thursday, reaching $14.17. The stock had a trading volume of 2,199,051 shares, compared to its average volume of 922,244. The business’s 50-day moving average price is $14.00 and its two-hundred day moving average price is $14.84. The company has a market cap of $1.24 billion, a P/E ratio of -6.14 and a beta of -1.51. Day One Biopharmaceuticals has a 12-month low of $9.67 and a 12-month high of $18.07.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price objective for the company from $11.00 to $24.00 in a report on Thursday. Piper Sandler reissued an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $35.71.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total transaction of $320,200.00. Following the transaction, the insider now owns 1,121,081 shares in the company, valued at approximately $17,948,506.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $16.01, for a total transaction of $320,200.00. Following the completion of the sale, the insider now directly owns 1,121,081 shares in the company, valued at approximately $17,948,506.81. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, General Counsel Adam Dubow sold 3,253 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $52,308.24. Following the completion of the transaction, the general counsel now owns 21,731 shares in the company, valued at approximately $349,434.48. The disclosure for this sale can be found here. Insiders have sold a total of 73,300 shares of company stock valued at $1,181,765 in the last ninety days. 8.40% of the stock is currently owned by corporate insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.